Immunotope, Inc. Awarded A US Army Phase II Contract To Develop Prostate Cancer Early Detection Test

Published: Oct 23, 2006

Doylestown, PA (PRWEB) October 20, 2006 -- Immunotope, Inc. a biotechnology company developing cancer diagnostics and immunotherapeutics, has been awarded a Phase II SBIR contract from the US Army to develop an autoantibody-based early-stage diagnostic test for prostate cancer. The two-year, $780,000 award will fund the development of a noninvasive, highly sensitive and selective blood test.

Back to news